Table 2.
Correlation between tumour microenvironment types and clinicopathological features of patients with gastric cancer
| Tumour microenvironment (by manual interpretation) | P values | ||||
| Type I (n=107) | Type II (n=66) | Type III (n=25) | Type IV (n=49) | ||
| No.(%) | No.(%) | No.(%) | No.(%) | ||
| Age | |||||
| <60 | 46 (43.0) | 38 (57.6) | 13 (52.0) | 26 (53.1) | 0.280* |
| ≥60 | 61 (57.0) | 28 (42.4) | 12 (48.0) | 23 (46.9) | |
| Sex | |||||
| Male | 86 (80.4) | 37 (56.1) | 19 (76.0) | 25 (51.0) | <0.001* |
| Female | 21 (19.6) | 29 (43.9) | 6 (24.0) | 24 (49.0) | |
| Location | |||||
| Antrum | 47 (43.9) | 26 (39.4) | 13 (52.0) | 17 (34.7) | 0.486* |
| Others | 60 (56.1) | 40 (60.6) | 12 (48.0) | 21 (65.3) | |
| Subtype | |||||
| EBV(+) | 37 (34.6) | 1 (1.5) | 1 (4.0) | 4 (8.2) | <0.001* |
| MSI-H | 50 (46.7) | 9 (13.6) | 6 (24.0) | 14 (28.6) | |
| EBV(-)/MSS | 20 (18.7) | 56 (84.8) | 18 (72.0) | 31 (63.3) | |
| Histological type by Lauren | |||||
| Intestinal | 48 (44.9) | 22 (33.3) | 13 (52.0) | 20 (40.8) | 0.001* |
| Mixed | 11 (10.3) | 5 (7.6) | 4 (16.0) | 2 (4.1) | |
| Diffuse | 37 (34.6) | 39 (59.1) | 8 (32.0) | 27 (55.1) | |
| Indeterminate | 11 (10.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Histological type by host inflammatory response | |||||
| CA | 33 (30.8) | 47 (71.2) | 19 (76.0) | 27 (55.1) | <0.001* |
| CLR | 50 (46.7) | 19 (28.8) | 6 (24.0) | 19 (38.8) | |
| LELC | 24 (22.4) | 0 (0.0) | 0 (0.0) | 3 (6.1) | |
| pT | |||||
| 1 | 10(9.3) | 5(7.6) | 1(4.0) | 0 (0.0) | 0.126† |
| 2 | 56(52.3) | 21(31.8) | 12(48.0) | 22 (44.9) | |
| 3 | 25(23.4) | 22(33.3) | 9(36.0) | 21 (42.9) | |
| 4 | 16(15.0) | 18(27.3) | 3(12.0) | 6 (12.2) | |
| pN | |||||
| 0 | 39 (36.4) | 12 (18.2) | 6 (24.0) | 12 (24.5) | 0.106† |
| 1 | 32 (29.9) | 28 (42.4) | 7 (28.0) | 18 (36.7) | |
| 2 | 28 (26.2) | 14 (21.2) | 4 (16.0) | 14 (28.6) | |
| 3 | 8 (7.5) | 12 (18.2) | 8 (32.0) | 5 (10.2) | |
| TNM stage | |||||
| I | 31(29.0) | 9(13.6) | 3(12.0) | 8(16.3) | 0.001† |
| II | 41(38.3) | 20(30.3) | 9(36.0) | 14(28.6) | |
| III | 32(29.9) | 30(45.5) | 11(44.0) | 19(38.8) | |
| IV | 3(2.8) | 7(10.6) | 2(8.0) | 8(16.3) | |
| Distant metastasis | |||||
| Absent | 103(96.3) | 56 (84.8) | 20 (80.0) | 39 (79.6) | 0.006* |
| Present | 4(3.7) | 10 (15.2) | 5 (20.0) | 10 (20.4) | |
*Pearson’s χ2 test.
†Linear-by-linear association.
CA, conventional adenocarcinoma; CLR, carcinoma with Crohn-like reaction; EBV, Epstein-Barr virus; LELC, lymphoepithelioma-like carcinoma; MSI-H, microsatellite instability-high; MSS, microsatellite stable; pT, pathologic T; pN, pathologic N, TNM, tumor/node/metastasis.